Jack Bendheim

CEO and 10% owner Jack Bendheim sells over $1M of PAHC shares across 7 transactions; all prior sales on this stock poorly timed as shares rose afterward.

Jack Bendheim, President, CEO, and 10% beneficial owner of Phibro Animal Health, divested over $1 million in shares across seven separate transactions over three trading days, reducing his holdings by roughly 18,600 shares. This marks his third major selling cycle in recent weeks—his two most recent sale batches just days earlier both saw the stock rise significantly afterward, a pattern consistent across all five of his prior sales on this ticker. The CEO is selling into strength: the stock trades near its recent highs and has staged a strong recovery over the past three months, making this timing notably different from his past sales, which typically preceded gains rather than pullbacks. Phibro remains a profitable, revenue-growing company, so this divestiture does not signal financial distress; rather, it represents a material reduction in Bendheim's personal exposure to a stock that has climbed substantially and at which he has been a net seller for months. Retail investors should note that concentrated insider selling—especially by a founder-aligned 10% owner—typically warrants closer examination, particularly when the seller's track record shows poor timing on similar exits.

CEO Jack Bendheim sold 21,120 shares across 7 transactions for $1,137,592.76 at PAHC, reducing stake 22.0%.

Jack Bendheim, President and CEO of Phibro Animal Health, executed 7 separate sales totaling 21,120 shares for $1,137,592.76 on April 28–30, 2026, at prices ranging from $52.65 to $56.69 (blended average $53.86). This represents a 22.0% reduction in his holdings, from 95,880 shares to 74,760 shares. The stock trades at $53.18 currently, down 10.7% from its 52-week high of $59.58 and down 3.8% over the last 30 days, though it has gained 32.4% over the past 90 days. Notably, Bendheim executed 5 prior sells at PAHC between April 21–23, 2026 (just days before this filing), suggesting a concentrated window of disposition activity. At a P/E of 39.69 and with the company posting 27.4% annual revenue growth and $27.5M net income on $373.9M quarterly revenue, the series of sales by the CEO warrants investor attention to assess whether the disposition signals an operational or strategic shift.

PAHC CEO Bendheim sells 21,120 shares across 5 transactions (04/21–04/23) for $1,157,091.23; holds 95,880 shares post-sale.

Jack Bendheim, President and CEO of Phibro Animal Health, executed 5 separate sales totaling 21,120 shares for $1,157,091.23 over three trading days (April 21–23, 2026) at prices ranging from $54.29 to $56.17, reducing his stake from 117,000 to 95,880 shares (-18.1%). The blended average sale price of $54.79 is slightly above the current market price of $54.69 and notably below the 52-week high of $59.58, placing these sales at -8.2% from peak. Recent same-ticker activity shows 5 prior sales within the preceding six days (April 15–16), suggesting an active disposition pattern. While Bendheim's cross-ticker track record shows 20 prior sales with an average 30-day return of +6.0%, the timing outcomes of those cross-ticker sales and this specific transaction at PAHC remain undetermined by historical patterns at this particular ticker. The company's fundamentals show strong momentum (revenue growth of +27.4% year-over-year, P/E of 40.81), but the rapid sequence of insider sales warrants attention to whether they reflect market-driven opportunism or a signal about near-term stock trajectory.

PAHC CEO Bendheim sold 21,120 shares over 3 days (Apr 14–16) for $1,201,595.13; holds 117,000 post-sale

Jack Bendheim, PAHC's President and CEO, executed 7 separate sales totaling 21,120 shares for $1,201,595.13 (blended average $56.89) across April 14–16, reducing holdings from 138,120 to 117,000 shares (-15.3%). The stock is currently at $53.88, down 9.6% from its 52-week high of $59.58, though up 31.2% over 90 days and 2.6% over 30 days. A FLAG indicates this filing involves a derivative-conversion transaction, meaning the Form 4 Table I holdings shown do not represent the insider's total position; derivative securities data (Table II) is not yet populated in the database. The company reports strong fundamentals (annual revenue growth of +27.4%, $373.9M latest-quarter revenue, $27.5M net income) but trades at a 40.21 P/E. His prior 5 sales at PAHC (late March 2026) are too recent to measure outcome, and none of his cross-ticker track record (20 prior sells, +1.3% average 30-day return) have yet demonstrated predictive timing at this specific ticker.

PAHC CEO Jack Bendheim sells 14,080 shares for $756,833.69 across 4 transactions, reducing stake 27.0%.

Jack Bendheim, President and CEO of Phibro Animal Health, executed 4 separate sales totaling 14,080 shares for $756,833.69 at an average price of $53.75 on March 30–31, 2026. This represents a 27.0% reduction in his post-transaction holdings to 38,120 shares. The sales occurred within 0.3% of the current price of $55.31 and slightly ahead of the 52-week high of $57.01. Bendheim's cross-ticker track record shows 20 prior sells averaging a +3.2% 30-day return after sale, indicating his prior open-market sells have historically been followed by stock appreciation rather than decline. At Phibro specifically, he has executed 5 prior sells within the past week (all on March 25–26), none yet measurable at the 90-day mark, establishing a recent pattern of regular dispositions in this stock. With the company trading at a P/E of 41.28 and annual revenue growth of +27.4%, the sales do not align with fundamentals deterioration but rather reflect a significant planned reduction in executive equity exposure.

PAHC CEO Jack Bendheim sold 21,120 shares for $1,166,104.52 across 7 transactions (March 24-26, 2026) at blended $55.21, reducing holdings by 28.8%.

Jack Bendheim, President and CEO of Phibro Animal Health, executed 7 separate sales totaling 21,120 shares for $1,166,104.52 over a three-day period (March 24-26, 2026), reducing his stake from 73,320 shares to 52,200 shares. The transactions occurred at prices ranging from $52.88 to $57.17, with a blended average of $55.21, near the current price of $55.82 and well above the 52-week high of $57.01. The 28.8% reduction in his holdings over three consecutive trading days represents a material liquidation. Notably, this follows closely on five other sales at PAHC conducted just one to five days prior (March 18-19, 2026), suggesting a deliberate multi-day execution of a larger position reduction. The stock has appreciated 46.2% over 90 days and 8.5% over 30 days, reflecting strong recent momentum in a company with accelerating fundamentals (27.4% annual revenue growth, $373.9M quarterly revenue, $27.5M net income, 41.66 P/E ratio).

PAHC CEO Bendheim sold 22,880 shares for $1.2M across 3 days; 5 prior sales at same ticker in Feb 2026

Jack Bendheim, President and CEO of Phibro Animal Health, executed 7 separate sales totaling 22,880 shares for $1,198,818.13 ($1.2M) at a blended average price of $52.40 across March 17–19, 2026, reducing his position by 23.8% from 96,200 to 73,320 shares. This sale follows a pattern of recent insider activity at the same ticker: Bendheim conducted 5 prior sells at PAHC on February 24–26, 2026, suggesting sustained capital allocation activity rather than a single discrete event. The company's fundamentals show strong growth (revenue up 27.4% year-over-year, $373.9M latest quarter) and profitability ($27.5M net income), though the stock trades at a P/E of 39.09 and is currently 4.2% below its 52-week high of $54.70. The transaction executed near the middle of the 52-week range and slightly above current price ($52.38), offering no clear timing signal relative to recent price momentum (90-day change +40.6%). Bendheim's cross-ticker track record shows 20 prior sells with an average 30-day return of -1.1%, but outcomes on his same-ticker PAHC sales from late February remain unmeasurable.

PAHC CEO Jack Bendheim sold 21,120 shares (-93.5% of holdings) for $1.1M across 5 transactions at $51.27–$54.28 on 2026-02-24 to 2026-02-26.

Jack Bendheim, PAHC's President and CEO, executed 5 separate sales totaling 21,120 shares for $1,103,937.67 across three consecutive trading days (2026-02-24 to 2026-02-26), reducing his position from 22,600 shares to 1,480 shares—a 93.5% reduction. The blended average price of $52.27 sits 4.4% below the current price of $54.70, which itself represents the stock's 52-week high (+0.0% from the peak). The CEO's near-complete liquidation of his position warrants investor attention, particularly given that PAHC's fundamentals show strong momentum: annual revenue growth of +27.4%, a market cap of $3,769,377,000.00, and recent quarterly revenue of $373,910,000.00 with net income of $27,459,000.00. The scale and speed of the divestiture—disposing of substantially all holdings over three days—combined with the stock's recent rally (+38.4% in 30 days, +30.6% in 90 days) provides context for evaluating whether the CEO's actions reflect external timing considerations or internal strategic factors.

PAHC CEO Bendheim sold 14,080 shares across 3 transactions (Feb 19-20) for $715,775.01, reducing holdings by 38.4%

Jack Bendheim, PAHC's President and CEO, executed 3 separate sales totaling 14,080 shares (14.1K shares) for $715,775.01 ($715.8K) between Feb 19-20, 2026, reducing his holdings from 36,680 to 22,600 shares at a blended average price of $50.84. The magnitude of this reduction—38.4% of pre-transaction holdings in a two-day window—represents a material decrease in his stake coinciding with the stock trading near its 52-week high of $53.07 (currently at $51.52, -2.9% from that peak). Notably, his recent prior trades at PAHC (5 separate sells since Feb 11, all outcomes still unmeasurable) suggest an ongoing pattern of liquidation; however, his cross-ticker track record shows 20 prior sells with an average 30-day return of +24.9%, a context that does not necessarily predict outcomes at this specific ticker. The company's fundamentals show healthy revenue growth of +27.4% year-over-year, though the P/E of 38.45 reflects elevated valuation, warranting investor attention to whether further insider sales signal a divergence between insider positioning and current market valuation.

CEO Bendheim sells 14,080 shares across three transactions for $727.6K; stock up 24.4% in 30 days, P/E 38.12.

Jack Bendheim, President and CEO of Phibro Animal Health Corp, executed 3 separate sales totaling 14,080 shares for $727,646.27 between February 10–18, 2026, reducing his holdings by -27.7% to 36,680 shares. The sales occurred at a blended average price of $51.68, close to the current price of $51.08 but notably above the 52-week low of $16.53—within 3.8% of the 52-week high of $53.07. The stock has risen +24.4% over the past 30 days and +25.2% over 90 days, reflecting strong recent momentum in a company with annual revenue growth of +27.4%, $373.9M quarterly revenue, and a P/E of 38.12. Bendheim's cross-ticker track record shows 20 prior sells with an average 30-day return of +28.8%, though his 5 prior same-ticker trades at PAHC lack measurable 30- or 90-day outcomes. The timing and scale of these sales during a high-valuation, rapid-growth phase merit observation, particularly given the elevated P/E and recent price acceleration.